365 related articles for article (PubMed ID: 34323012)
41. The association between anogenital distance and benign prostatic hyperplasia related lower urinary tract symptoms in Chinese aging men.
Lu Y; Fan S; Song Y; Liu K; Zhou K; Kang J; Wang S; Yang Y; Liu X
World J Urol; 2021 Jul; 39(7):2645-2653. PubMed ID: 33141318
[TBL] [Abstract][Full Text] [Related]
42. Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.
Kardasevic A; Milicevic S
Med Arch; 2017 Feb; 71(1):32-36. PubMed ID: 28428671
[TBL] [Abstract][Full Text] [Related]
43. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.
Park JS; Koo KC; Kim HK; Chung BH; Lee KS
Medicine (Baltimore); 2019 Oct; 98(42):e17635. PubMed ID: 31626149
[TBL] [Abstract][Full Text] [Related]
44. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
[TBL] [Abstract][Full Text] [Related]
46. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
[TBL] [Abstract][Full Text] [Related]
47. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates.
Egan KB
Urol Clin North Am; 2016 Aug; 43(3):289-97. PubMed ID: 27476122
[TBL] [Abstract][Full Text] [Related]
48. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
49. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
50. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
Nickel JC; Elhilali M; Vallancien G;
BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
[TBL] [Abstract][Full Text] [Related]
51. Overactive bladder (OAB): A symptom in search of a disease - Its relationship to specific lower urinary tract symptoms and conditions.
Van Batavia JP; Combs AJ; Fast AM; Glassberg KI
J Pediatr Urol; 2017 Jun; 13(3):277.e1-277.e4. PubMed ID: 28527720
[TBL] [Abstract][Full Text] [Related]
52. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
53. Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?
Bang WJ; Lee JY; Koo KC; Hah YS; Lee DH; Cho KS
Urology; 2014 Sep; 84(3):670-4. PubMed ID: 25168549
[TBL] [Abstract][Full Text] [Related]
54. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
Nik-Ahd F; Lenore Ackerman A; Anger J
Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
[TBL] [Abstract][Full Text] [Related]
55. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Freedland SJ; Csizmadi I
Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
[TBL] [Abstract][Full Text] [Related]
56. Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis.
Nandalur KR; Walker D; Ye H; Al-Katib S; Seifman B; Gangwish D; Dhaliwal A; Connor E; Dobies K; Sesoko C; Dejoie W; Zwaans B; Nandalur S; Nguyen J; Hafron J
Prostate; 2023 Feb; 83(3):259-267. PubMed ID: 36344473
[TBL] [Abstract][Full Text] [Related]
57. The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study.
Xue Z; Lin Y; Jiang Y; Wei N; Bi J
BMC Urol; 2018 Dec; 18(1):115. PubMed ID: 30545338
[TBL] [Abstract][Full Text] [Related]
58. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
59. Comparison of IPSS score and voiding parameters in men presenting with LUTS.
Kohler TS; Kausik SJ
Can J Urol; 2023 Oct; 30(5):11668-11675. PubMed ID: 37838994
[TBL] [Abstract][Full Text] [Related]
60. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder.
Hagovska M; Svihra J; Macko L; Breza J; Svihra J; Luptak J; Lachvac L
World J Urol; 2024 May; 42(1):287. PubMed ID: 38698269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
